The Importance of RWE Strategy Planning

In this special podcast episode in honor of Rare Disease Day 2024, Angela Wheeler, President of Insight at Lumanity and Dr. Karin Hoelzer, Director of Policy and Regulatory Affairs at the National Organization for Rare Disorders (NORD), discuss opportunities for pharmaceutical companies to work with and support rare disease communities.

Learn how NORD is strengthening collaboration between pharmaceutical companies and rare disease communities, and examples of the positive impact that can be made when pharmaceutical companies, organizations like NORD, and patient advocates join together.

Listen to the full episode to hear Angela ask Karin some important questions, including: 

• What are the biggest opportunities for the rare disease communities in 2024?
•  What are some lessons learned for fruitful collaboration between pharma companies and rare disease communities and organizations like NORD?
• What policy priorities is NORD focused on in 2024?
• What role can patient advocates and pharma play in supporting the rare disease community on these issues?

In this podcast episode, we explore the rich potential of social media listening (SML) insights, and how, when interpreted and acted on, they can have a significant impact on commercial decision-making.

Hear from Lumanity experts as they bring SML to life using several real world examples.

Topics include:

• How the agility, flexibility and insights from SML research are being harnessed to help improve commercial decisions
• How SML best complements traditional research and data
• The value of SML in reaching conversation leaders, HCPs and patient advocates
• The value for detecting commonalities and patterns, as well as perception changes over time
• How to ensure these insights are actionable - and what not to do

In this podcast episode, we explore the fascinating world of artificial intelligence and its impact on the healthcare industry, as well as the ever evolving realm of research and its potentially transformative power on decision making.

Hear from Lumanity experts Damian Eade, Head of Digital Insights and Analytics, Gemma Spickernell, Director of Behavioral Science, and Andrew Wood, Head of Behavioral Science as they discuss how to navigate the balance between the benefits of AI while ensuring accuracy and integrity in research.

This thought-provoking conversation considers the potential of Generative AI, it's application and implications in the near term, including:

• The potential creative capabilities of Generative AI and the implications for enhancing efficiency
• The strategic integration of insights from various sources to drive decision-making
• The critical role of researchers in maintaining the values and integrity of research

There are incredible synergies with joint HEOR and Real World Evidence (RWE) projects, but there are also unique challenges. In this podcast episode, The Importance of RWE Strategy Planning, Ann-Marie Chapman, Nikita Jeswani, Meena Venkatachalam, and Alex Thorel discuss the use cases and planning for RWE, identifying appropriate RWE, and RWE trends. 

Listen to this podcast to learn:

·         Key considerations, steps, and recommendations in identifying appropriate data sources

·         Where RWD and RWE are leveraged most across the product lifecycle

·         The length of time it takes to initiate an RWE study

·         The common mistakes in RWE study planning

·         The major changes in the RWD space over the last 10 years and in the future

Strategic risk is often overlooked within the pharmaceutical industry. There’s a perception that someone else is picking up the risk ball. Or there is more of a focus on internal risks, with little thought to the larger external factors that can have a significant impact on your launch.

We see common risks arise from competitor launches, multi-indication launches, and supply chain issues. Unmitigated risks can lead to costly delays. So, what can you do to identify the risks for your asset launch and successfully mitigate them?

In our latest Launch Excellence Alchemy podcast, our team of experts discuss and share their thoughts, tips, and solutions, with a focus on:

• The common strategic risks that arise during the launch of an asset
• Why it’s important to create a strategic risk system to monitor these risks
• Creating an appropriate plan to mitigate risks and identifying who is accountable

Join John Crick, Launch Excellence Project Lead, Penny Matthews, Managing Consultant for Ignite™, and Andrew Coates, Risk Management Expert as they share ideas to think outside the box when it comes to risk management.

We know that effective collaboration across cross-functional and global/local launch teams is one of the critical elements to launch success – but teams often struggle to develop the right behaviors that foster a truly collaborative culture. Leadership styles too play a vital role, with research directing us away from ‘leading from the front’, towards a model that champions interdependent leadership and shared accountability.

In the second episode of our series on launch excellence, we explore how:

• Heroic leadership styles can hinder collaboration when launching a product
• Looking at your own behaviors and mindset can create the biggest catalyst for change in driving collaboration
• External partners and a ‘third voice’ can be critical in your journey to fostering collaboration
  

Join Lumanity staff Tracey Barnes, Vice President of Launch Excellence, and Ollie Roberts, a Pharma Launch Expert, as they share their experience and define the critical steps to becoming a more effective launch collaborator.

In this episode, Dr. Nancy McGee and Rob Rawlinson discuss potential implications of the Inflation Reduction Act (IRA) legislation that was passed in the U.S. in 2022.

This episode covers:

• An overview of the IRA in relation to healthcare
• The potential impacts for oncology patients, manufacturers, and oncologists
• The impact of the legislation outside of the U.S.

Speakers:

• Nancy McGee, JD, MPH, DrPH, Senior Vice President, Health Policy & Public Payers, Lumanity
• Rob Rawlinson, Director, Oncology Insights Lead, Lumanity

©2023 Lumanity Inc.

During the launch of a new medicine, there is so much focus on the intellectual strategy, that it's easy to sideline thoughts about "How are we going to collaborate as a team to make this happen?"

But statistics show that strong teamwork can deliver up to 3x more shareholder value. Investing time in good cross-functional collaboration is not just a nice-to-have, it's a must-have for successful launch teams.

In the first episode of our series on launch excellence, we explore the following:

• How strong internal collaboration delivers optimal launch outcomes
• Why a team ‘contract’ can transform a launch team’s ways of workings
• The role leadership plays in driving cross-functional launch alignment and how much influence it delivers to success

Join Lumanity staff Tracey Barnes, Vice President of Launch Excellence, and Kirsty Tait, a leading Launch Excellence Consultant, as they untangle the intricacies of cross-functional collaboration to share what good launch teams are doing that sets them apart from the rest.

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead at Lumanity, sits down to talk about relevant and important content.

In this sixth episode, Joel sits down with the CEO and CMO of ImCheck Therapeutics to discuss:

• Company origins, focus, and fundraising performance to date
• Role of butyrophilins (BTNs) as an novel therapeutic target to boost antitumor immunity
• Performance of ICT01, Imcheck’s clinical-stage lead program targeting BTN3A in gamma-delta T-cells
• Positioning and commercial strategy in the post-PD1 solid-tumor landscape

Episode Guests:

• Pierre d’Epenoux, CEO, ImCheck Therapeutics
• Paul Frohna, CMO, ImCheck Therapeutics

©2023 Lumanity Inc.

In this podcast series, Joel Sandler, Principal, Cancer Cell Therapy Lead, sits down to talk about relevant and important content.

In this fifth episode, Joel sits down with Brian Leyland-Jones, MB BS, PhD, CMO, National Foundation for Cancer Research and Peter Kuhn, PhD, Dean’s Professor of Biological Sciences, Professor of Biological Sciences, Medicine, Biomedical Engineering, Aerospace and Mechanical Engineering and Urology, to explore:

• Historical perspective on personalized approaches to cancer treatment
• Liquid biopsy as a means to facilitate adaptive treatment regimens tailored to individual cancers
• Vision of where the field is going and future management paradigms

©2023 Lumanity Inc.